T-Lymphocyte Activation Is Correlated With the Presence of Anti-EBV in Patients With Laryngeal Squamous Cell Carcinoma

Abstract

Background/Aim: Chronic viral infection is an important risk factor in the development of cancer. Failure of immune response to clear the oncogenic infection can facilitate cancer progression. The aim of the present study was to analyze early and late activation of T-lymphocytes related to Epstein-Barr virus (EBV) infection by the expression of markers of activation (CD69, CD25) on the surface of Tlymphocytes (CD3 + , CD4 + , CD8 +) in patients bearing laryngeal cancer according to absence/presence immunoglobulin G antibodies to EBV nuclear antigen (EBNA1). Materials and Methods: Thirty-three patients with laryngeal squamous cell carcinoma (LC) and 20 volunteers without cancer (control group) were enrolled in the study. Peripheral blood samples were collected from every individual. The markers of activation of T-lymphocytes were determined by flow cytometry, whereas commercial immunoenzymatic assay kits were used for detection of anti-viral capsid antigen (VCA) IgM, anti-VCA IgG, and anti-EBNA1 IgG. Results: Increased early activation of CD8 + and CD4 + T-lymphocytes was found in patients with LC. There was a significantly higher proportion of CD4 + and CD8 + T-lymphocytes expressing CD69 antigen in patients with LC compared to the control group. The proportion of CD4 + CD25 + T-lymphocytes in patients with LC positive for anti-EBNA1 IgG and anti-VCA IgM was lower compared to patients without antibodies to VCA IgM. Conclusion: The dysfunction of immune response in larynx cancer patients could be associated with EBV infection.

Effects of Epstein-Barr Virus Infection on the Risk and Prognosis of Primary Laryngeal Squamous Cell Carcinoma: A Hospital-Based Case-Control Study in Taiwan

“…Therefore, dysfunction of the immune response in removing the oncogenic EBV infection may increase the risk of cancer progression. Although we did not find a significant association between CD3 expression and EBV infection in the larynx, patients with LSCC and EBV infection may have a lower proportion of late activated T lymphocytes in the peripheral blood compared to patients without EBV infection [70]. Therefore, investigating peripheral blood T lym-phocytes may help us to comprehensively understand the possible mechanisms of LR and relapse in EBV-related LSCC.…”

Epstein-Barr Virus-Associated Carcinoma of the Larynx: A Systematic Review with Meta-Analysis

“…The 31 systematically reviewed studies were carried out in 19 different countries in Europe (n = 12) [6,[10][11][12][13][14][15][16][17][18][19][20], Asia (n = 8) [21][22][23][24][25][26][27][28], North America (n = 5) [3,[29][30][31][32], Eurasia (n = 3) [4,5,33], Oceania (n = 1) [34], South America (n = 1) [2], and concomitantly in North America and Europe (n = 1) [35] (Table 1).…”

“…In this scenario, Epstein-Barr virus (EBV) arises as a potential candidate considering all the evidence gathered so far on its oncogenic role in several lymphoid and epithelial malignancies, including head and neck squamous cell carcinomas (HNSCC) [5]. EBV is etiologically linked to undifferentiated nasopharyngeal carcinoma (NPC) [6], and a recent meta-analysis has shown that EBVinfected individuals have a 2.5 times higher risk for developing oral carcinoma [7].…”

RNA-Seq revealing the tumor immunity regulation mechanism of circular RNA in human laryngeal squamous cell carcinomas

“…CircRNA have an important regulatory function in disease by interacting with disease-related miRNA [5]. According to a paper published in 2015, circRNA can already be used as a reliable biological signal for cancer diagnosis [6]. Moreover, in recent years, there have been literatures showing that the expression of some circRNA in LSCC patients is signi cantly different from that in normal adjacent tissues, and it is believed that there are potential new biomarkers in these signi cantly different circRNA [7].…”